StockNews.com started coverage on shares of Genocea Biosciences (NASDAQ:GNCA – Get Free Report) in a research note issued on Monday. The firm set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Price Performance
Shares of NASDAQ GNCA opened at $0.00 on Monday. The stock has a market cap of $5,873.00, a P/E ratio of 0.00 and a beta of 1.61. Genocea Biosciences has a 1-year low of $0.00 and a 1-year high of $0.00. The company has a debt-to-equity ratio of 0.24, a quick ratio of 1.35 and a current ratio of 1.35.
About Genocea Biosciences
Featured Stories
- Five stocks we like better than Genocea Biosciences
- How to Most Effectively Use the MarketBeat Earnings Screener
- 3 Stocks That Could Rise on European Bank Interest Rate Cuts
- Best Stocks Under $10.00
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- Dividend King Proctor & Gamble Is A Buy On Post-Earnings Weakness
- MarketBeat Week in Review – 9/16 – 9/20
Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.